PF-06263276   Click here for help

GtoPdb Ligand ID: 9432

Synonyms: compound 2 [PMID: 27983835] | PF 0626327 | PF0626327
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-06263276 is a pan-JAK inhibitor [1]. There are two E/Z isomers as PubChem CID 122196621 and PubChem CID 71495793 but these are not resolved in the publication.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 126.92
Molecular weight 566.26
XLogP 5.55
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCc1cc(O)c(cc1c1ccc2c(c1)[nH]nc2c1nc2c([nH]1)CCN(C2)C(=O)c1cnc(cn1)N1CCCCC1)F
Isomeric SMILES CCc1cc(O)c(cc1c1ccc2c(c1)[nH]nc2c1nc2c([nH]1)CCN(C2)C(=O)c1cnc(cn1)N1CCCCC1)F
InChI InChI=1S/C31H31FN8O2/c1-2-18-13-27(41)22(32)14-21(18)19-6-7-20-24(12-19)37-38-29(20)30-35-23-8-11-40(17-26(23)36-30)31(42)25-15-34-28(16-33-25)39-9-4-3-5-10-39/h6-7,12-16,41H,2-5,8-11,17H2,1H3,(H,35,36)(H,37,38)
InChI Key XDJGNPSZQSWJCV-UHFFFAOYSA-N
Immunopharmacology Comments
PF-06263276 is predicted to offer local anti-inflammatory effects in inhaled or topically applied formulations, thus minimising risk of systemic JAK inhibitor side-effects [1].
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic obstructive pulmonary disease Disease Ontology: DOID:3083
Predicted to offer clinical anti-inflammatory effects in COPD.
Psoriasis Disease Ontology: DOID:8893
Completed Phase 1 trial in plaque psoriasis patients (see NCT02193815)